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Based on BODIPY molecular rotor and zinc-dipicolylamine receptor, we designed a fluorogenic probe for detection of apoptosis. Being 
poorly emissive in solution and with healthy cells, it selectively binds phosphatidylserine of early apoptotic cells and internalizes into late 
apoptoric cells, lighting up its green fluorescence. 
Cell plasma membranes are asymmetric, wherein the zwitterionic phosphatidylcholine (PC) is present in the outer leaflet of the 
bilayer and the anionic phosphatidylserine (PS) is exclusively located in the inner leaflet.1-5 During the early stages of apoptosis, 
the activity of scramblases increases, leading to the exposure of PS on the cell surface.6-9 The presence of anionic PS on the cell 
surface is a hallmark of apoptosis and it is responsible for the daily clearance of dead cells from the body by macrophages.10,11 
Moreover, the therapeutic efficacy of the anticancer drugs could be determined by monitoring the apoptosis.12 Hence, apoptosis 
detection is very important from the biological and clinical standpoint.  
 A number of methods were developed for apoptosis detection, which include monitoring the caspase activation,13-15 DNA 
fragmentation,16 activity of mitochondria,17,18 or changes in lipid organization at the outer membrane leaflet.19,20 One of the most 
widely used methods is based on fluorescently labelled Annexin V, a calcium-dependent protein with a high-affinity for PS (Kd = 
0.1 nM) on the surface of apoptotic cells.21 However, it has certain limitations,22 such as short shelf life and relatively slow 
binding,23,24 which requires millimolar concentrations of extracellular Ca2+.25 In live cell imaging, washing steps are required to 
remove the unbound Annexin V protein, a source of background fluorescence. Differentiation between early and late apoptosis is 
not possible with Annexin V, as often the case with many reported probes.15,19,20,26 Recently, fluorescently labelled cationic 
dipicolylamine-zinc (DPA-Zn) complexes were reported as the alternatives to Annexin V reagents.26 These DPA-Zn complexes 
interact strongly and specifically with anionic PS-rich membranes, allowing the apoptosis detection. However, most of these probes 
suffer from intrinsic fluorescence27-29 and the probes that fluoresce only after PS binding are still rare in the literature.30-32 
Moreover, differentiation of early vs. late stage apoptosis by these probes remains a challenge.30  
 Fluorogenic probes that turn ON their fluorescence upon interaction with the target are useful for background-free imaging.33 
One such approach to achieve turn ON response is to use the molecular rotors, dyes undergoing intramolecular rotation that 
provides an efficient pathway for the nonradiative relaxation.34-37 Importantly, an increase in the surrounding viscosity slows down 
this rotation, resulting in their fluorescence turn-ON. Molecular rotors were successfully used as viscosity probes in live cells,36,38 
cell membranes,39,40 as well as fluorogenic reporters of protein assembly41 and interactions of nucleic acids.42 An attractive 
approach is to convert molecular rotors into turn ON probes for detecting biomolecular targets, although it was only realized for 
sensing oxytocin receptor.43  
Herein, based on BODIPY molecular rotor, we designed a fluorogenic probe for apoptosis detection (BPDPA-Zn, Scheme 1). 
BPDPA-Zn showed turn-ON fluorescence response upon binding to negatively charged PS-rich membranes in early apoptotic cells 
and strong intracellular fluorescence in late apoptotic cells, which allowed distinguishing them with good signal to background 
ratio. 
BPDPA-Zn probe is composed of three functional parts: (i) a BODIPY-based molecular rotor, the fluorophore exhibiting strong 
viscosity dependent emission;34-39 (ii) a recognition unit for PS based on DPA-Zn; (iii) a PEG-12 spacer connecting the dye with the 
recognition unit. The PEG spacer was previously shown to not only improve the solubility of probes, but also prevent their non-
specific interactions with cell plasma membranes.44 To obtain BPDPA-Zn, a BODIPY molecular rotor bearing carboxy group was 
first synthesized and then coupled with a PEG-12 amino-azide spacer, giving azide derivative 1 (Scheme 1a, see ESI† for details). 
Then, bis-dipicolylamine (bis-DPA) ligand, bearing phenol function, was prepared45 and further O-alkylated with propargyl 
bromide, yielding alkyne derivative 2. Azide-alkyne click reaction of 1 and 2, followed by complexation with Zn(NO3)2 in 
methanol/water mixture (1/1, v/v), resulted in the final probe BPDPA-Zn. 
 
 
Scheme 1 a) Synthesis of BPDPA-Zn probe; b) Schematic representation of BPDPA-Zn binding to the PS-containing membrane surface and the resultant fluorescence light-up of the 
molecular rotor.  
 
 BPDPA-Zn showed absorption and emission bands centred around 498 and 514 nm, respectively, characteristic for the parent 
BODIPY dyes46 (Fig. S1). To validate the molecular rotor property in the BPDPA-Zn probe, viscosity effect on the fluorescence 
characteristics was evaluated in methanol/glycerol binary mixture (Fig. 1). The probe showed low fluorescence quantum yield (Φf) 
and lifetime (f) in pure methanol (Φf = 0.02, f = 0.30 ns), suggesting an efficient fluorescence quenching through intramolecular 
rotation. With increase in viscosity from 0.6 to 1317 cP, Φf increased 29-fold, while and f increased from 0.30 to 4.22 ns (Fig. 1a,c, 
Table S1. The radiative (kr) and non-radiative (knr) rate constants calculated from the Φf and τf values revealed that kr remained 
largely constant (0.06 – 0.15 ns-1) over the entire viscosity range (Table S1). However, the value of knr decreased sharply from 3.27 
ns-1 at 0.6 cP to 0.10 ns-1 at 1317 cP. These changes in the rate constants confirm that the observed increase in fluorescence 
efficiency at higher viscosity is due to the suppression of non-radiative processes as reported earlier for the parent BODIPY rotor.36-
39,47 As expected, we found a linear correlation of log f values versus log viscosity according to the Förster–Hoffmann equation 
with a slope of the plot of 0.6 (Fig. 1c), in agreement with the literature data for BODIPY molecular rotors.48 The similar trend was 
also observed for the logarithmic plot of f vs viscosity (Fig. 1d). Finally, BPDPA-Zn showed no solvatochromism in both absorption 
and fluorescence spectra in all the solvents studied (Table S2), suggesting negligible change in its dipole moment on the electronic 
excitation. f remained very low (Table S2, Fig. S2), with only a marginal increase upon decrease in solvent polarity (Φf = 0.020 in 
methanol = 32.6, and Φf = 0.065 in chloroform = 4.81). However, this effect is significantly smaller than that for twisted 
intramolecular charge transfer (TICT) rotors.34,35,43 Hence, similarly to parent BODIPY rotor, BPDPA-Zn directly reports the 
environment microviscosity irrespectively of the polarity. 
 
Fig. 1 Fluorescence characterisation of BPDPA-Zn (1 μM) in methanol/glycerol mixtures of varied viscosity as shown in the colour code recorded at 20 ˚C. a) Fluorescence spectra 
(ex = 480 nm); b) Plot of fluorescence quantum yield as a function of viscosity. Inset shows the linearity in the selected region of viscosity obtained in the log plot; c) Fluorescence 
decay profile (ex = 443 nm and em = 515 nm); the dotted line corresponds to the laser profile. d) Log plot of fluorescence lifetime vs. viscosity according to the Förster–Hoffmann 
equation. Estimated measurement errors were 5% for the quantum yield and 2% for the lifetime. 
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 To further study the probe response to PS-rich membranes, we prepared liposomes composed of (i) entirely zwitterionic lipid 
PC to mimic the uncharged membrane surfaces of healthy cells, and (ii) mixtures of PC and PS to mimic the apoptotic cell surface. 
The absorption spectrum of BPDPA-Zn in these liposomes showed only limited changes (Fig. S3). On the other hand, a gradual 
increase in the fluorescence intensity was observed as the fraction of PS increased from 5 to 50% (Fig. 2a). Then, we carried out 
studies with bovine serum albumin (BSA, the major component of serum) and other model lipid membranes composed of 
sphingomyelin/cholesterol (SM/Chol), dioleoylphosphatidylcholine (DOPC) and DOPC/cholesterol. Importantly, BPDPA-Zn did not 
show any significant enhancement in Φf for BSA or any of the zwitterionic lipid vesicles without PS. The incorporation of polar 
PEG12 chain in the probe probably helps to prevent the nonspecific interaction of the dye, as it was previously shown with a 
solvatochromic dye, Nile Red derivative.44 This result confirmed that BPDPA-Zn specifically binds to the anionic PS, which induces 
an insertion of BODIPY molecular rotor into the lipid bilayer. This insertion may sterically hinder the intramolecular rotation of the 
rotor (Scheme 1), which results in the observed fluorescence enhancement, as in the viscosity dependence experiment. However, 
the fluorescence enhancement in case of lipid membranes was smaller, because their microviscosity (140 ± 40 cP)36 is much lower 
than that of glycerol (1410 cP). 
   
 
Fig. 2 a) Fluorescence response of BPDPA-Zn (1 μM) in phosphate buffer (20 mM, pH 7.4) with various large unilamellar vesicles and BSA. a) Fluorescence spectra (ex = 480 nm) in 
the presence of vesicles with varied fraction of PS in PC; b) Ratio of quantum yield in the presence of serum protein or different lipid vesicles to that in phosphate buffer. Concentration 
of BSA and lipids was 20 and 200 M, respectively. 
The observed selectivity of the BPDPA-Zn to anionic vesicles inspired us to explore the possibility of using the probe for 
apoptosis detection. First, HeLa cells were treated with different concentrations of staurosporine for 2 h to induce early as well as 
late apoptosis.30,49 The cells were subsequently stained with BPDPA-Zn (1 µM) and commercially available apoptosis marker based 
on labelled Annexin V (Alexa Fluor 568 conjugate), which specifically recognizes exposed PS in apoptotic cells.6,50 For the early-
state apoptosis treatment (1 μM staurosporine),30 only the cells labelled Annexin V exhibited bright green fluorescence of BPDPA-
Zn, with good co-localization of both markers at the plasma membrane  (Fig 3a). These observations indicated that BPDPA-Zn is 
able to anchor to the membrane of early-stage apoptotic cells. Treatment of cells with 3 µM staurosporine, reported to induce late 
apoptosis,49 resulted in strong intracellular fluorescence of BPDPA-Zn (Fig 3b), in contrast to the labelled Annexin V that remained 
at the cell surface. Remarkably, healthy HeLa cells observed in the bright field but not labelled with Annexin V, showed no 
fluorescence signal of BPDPA-Zn (Fig. 3).  This result confirmed the specificity and efficacy of BPDPA-Zn for the detection of 
apoptosis.  
Next, flow cytometry has been carried out with both BPDPA-Zn and Annexin V Alexa Fluor 568. Normal cells stained with 
BPDPA-Zn and Annexin showed up in a quadrant Q1 of the dot plot, indicating weak fluorescence signal for both markers (Fig. 4). 
Whereas, the cells treated with staurosporine at intermediate concentration (2 μM) showed significant intensity increase for both 
markers used separately (in Q2 and Q4). For double-labelling, Annexin-positive cells were also BPDPA-Zn-positive (in Q3), 
confirming sensitivity of the latter to apoptosis. However, in contrast to Annexin, BPDPA-Zn showed two cell populations (P1 and 
P2), presumably early and late apoptotic cells. To prove that, we treated the cells with 3 μM staurosporine (favouring late 
apoptosis) and co-stained with propidium iodide (PI), a dead/necrotic cells indicator. As shown in Fig. S4, P1 population of BODIPY-
positive cells was PI-negative (Q2), whereas P2 corresponded to PI-positive cells (Q3). Therefore, P1 and P2 can be assigned to 
early and late apoptotic cells, respectively. Higher intensity in case of late vs early apoptotic cells can be explained by the probe 
internalisation (Fig. 3), which contributes to the signal enhancement. These results showed that our probe BPDPA-Zn can 
differentiate early and late apoptosis, which is not possible with the Annexin assay.                    
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 Fig. 3 Fluorescence images of early and late apoptotic HeLa cells induced by 1 and 3 μM staurosporine, respectively, for 2 h at 37˚C, which were stained with BPDPA-Zn (1 μM, green) 
and Annexin V Alexa Fluor 568 (0.5% v/v, red). Spinning disk imaging mode was used; BPDPA-Zn and Annexin V Alexa Fluor 568 were excited with 488- and 532-nm lasers, respectively, 
while emission was detected using 530/30 and 600/50 nm band-pass filters, respectively. Images were captured after 15 minutes incubation at 20˚C with the probes. Scale bar = 20 
m.  
 
Fig. 4 a) Representative flow cytometry dot plot of normal cells and apoptotic HeLa cells induced by 2 μM staurosporine for 2  h at 37˚C, which were either stained with BPDPA-Zn (1 
μM), Annexin V Alexa Fluor 568 (0.5% v/v) or both. b) The corresponding flow cytometry histograms showing cell counts vs. fluorescence intensity for BODIPY or Alexa 568 channel. 
BODIPY and Aleaxa Fluor 568 were excited at 488- and 561-nm lasers, respectively, while their fluorescence was collected at 525/50 and 615/20 nm, respectively. P1 and P2 
represents early and late apoptotic cells, respectively.  
 In summary, we propose an original design of fluorescent probe for detection and differentiation of early and late apoptosis 
based on fluorogenic viscosity-dependent character of molecular rotors. The developed probe (BPDPA-Zn) is composed of a 
BODIPY molecular rotor bearing through a PEG12 linker a ligand specific to PS, an anionic lipid exposed in apoptotic cells. The 
fluorescence quantum yield and the lifetime of the probe confirmed its molecular rotor properties. BPDPA-Zn specifically binds to 
model lipid membranes containing anionic phospholipid PS, resulting in significant fluorescence enhancement. It lights up 
apoptotic cells in green fluorescence, while showing no signal in healthy (HeLa) cells. The response of the probe correlates well 
with commercial apoptosis marker Annexin V and in addition, the probe differentiates between early and late apoptotic cells, due 
to its capacity to enter the latter. To the best of our knowledge, this is the first report on designing an apoptosis probe based on a 
molecular rotor dye and the first PS-targeting probe that distinguishes early and late apoptotic cells based on fluorescence 
intensity. Our results open a route to fluorogenic probes for apoptosis detection and suggest molecular rotors as promising building 
blocks for fluorogenic biosensors. 
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